1.	Phase III Randomized Study of Erlotinib in Patients With Incurable Stage IIIB or IV Non-Small Cell Lung Cancer Refractory to Standard Therapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAN-NCIC-BR21, OSI-CAN-NCIC-BR21, NCT00026325, BR21
2.	Phase III Randomized Study of Gemcitabine With or Without Erlotinib in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAN-NCIC-PA3, OSI-CAN-NCIC-PA3, NCT00026338, PA3
3.	Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Erlotinib (Tarceva) in Patients With Chemotherapy Naive Stage IIIB or IV Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENENTECH-OSI2298g, MSKCC-01122, NCT00029016
4.	A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OSI3199g, NCT00091663
5.	A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OSI3364g, NCT00130728
6.	Phase III Randomized Study of Maintenance Therapy Comprising Erlotinib Versus Observation in Patients With High-Risk Stage I or Stage II-IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Previously Treated With First-Line, Platinum-Based Chemotherapy Phase: Phase III Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: EORTC-55041, EUDRACT-2004-004333-34, NCT00263822
7.	A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AVF3671g, NCT00257608
8.	Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986
9.	Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D4200C00057, EUDRACT No. 2006-000259-16, NCT00364351
10.	A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO18192, NCT00556712
11.	Phase I/II Study of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-002, NCI-5380, CAN-NCIC-IND157, 5380, NCT00030576, IND157
12.	Phase I/II Study of Erlotinib in Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-0103, NCI-03-C-0114, NCT00045110, NABTC-01-03
13.	Phase I/II Study of Erlotinib, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Patients With Metastatic Colorectal Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-02039, NCI-5371, 5371, NCT00049101
14.	Phase I/II Study of Erlotinib and Docetaxel in Patients With Locally Advanced, Metastatic, or Recurrent Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: OSU-02H0084, OSU-0213, NCI-5393, NCT00055770, 5393
15.	Phase I/II Randomized Study of Bevacizumab and Erlotinib in Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-11956A, NCI-5701, UCCRC-NCI-5701, NCT00055913, 5701
16.	Phase I/II Study of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J0384, UCCRC-12202A, NCI-5948, NCT00063895, 5948
17.	Phase I/II Study of Erlotinib and Temsirolimus in Patients With Recurrent Malignant Glioma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-0402, NCI-06-C-0053, NABTC-04-02, NCT00112736
18.	Phase I/II Study of Erlotinib in Combination With Docetaxel and Carboplatin as Front-Line Therapy Followed by Maintenance Therapy With Erlotinib in Patients With Newly Diagnosed Stage III or IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PSOC-2001, AVENTIS-PSOC-2001, PSOC-IRB-5689, NCT00217529
19.	Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Not specified Sponsor: Other Protocol IDs: 7077, NCT00140556
20.	Phase I/II Study of Neoadjuvant Therapy Comprising Erlotinib Hydrochloride, Paclitaxel, and Carboplatin in Combination With Accelerated Hyperfractionated Radiotherapy Followed by Maintenance Therapy With Erlotinib Hydrochloride in Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: CASE-CCF-5876, CASE-CCF-0839, NCT00278148
21.	Phase I/II Pilot Study of Adjuvant Celecoxib and Erlotinib Hydrochloride in Patients With Hepatocellular Carcinoma at High Risk for Recurrence Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UCSF-04459, UCSF-H43059-26066-02, NCT00293436
22.	Phase I/II Study of Docetaxel and Erlotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors (Phase I Portion of Study Completed as of 12/01/2004) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: UCDCC-128, UCDCC-200311717-5, AVENTIS-Z1001055, NCT00390429
23.	Phase I/II Study of Two Different Schedules of Pemetrexed Disodium and Erlotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UCDCC-159, UCDCC-200412741-2, NCT00387322
24.	A Study of Enzastaurin and Erlotinib in Patients With Solid Tumors and Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11183, H6Q-MC-S030, NCT00452413
25.	Phase I/II Study of Neoadjuvant Chemoradiotherapy Comprising Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Followed by Surgical Resection and Consolidation Therapy Comprising Erlotinib Hydrochloride in Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CCCWFU-60106, CCCWFU-IRB00000695, SANOFI-AVENTIS-OX-05-013, CCCWFU 60106, NCT00499564